Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UNITED THERAPEUTICS (UTHR) Total Current Liabilities: 2009-2024

Historic Total Current Liabilities for UNITED THERAPEUTICS (UTHR) over the last 16 years, with Dec 2024 value amounting to $738.1 million.

  • UNITED THERAPEUTICS's Total Current Liabilities fell 37.45% to $546.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $546.3 million, marking a year-over-year decrease of 37.45%. This contributed to the annual value of $738.1 million for FY2024, which is 8.24% down from last year.
  • According to the latest figures from FY2024, UNITED THERAPEUTICS's Total Current Liabilities is $738.1 million, which was down 8.24% from $804.4 million recorded in FY2023.
  • In the past 5 years, UNITED THERAPEUTICS's Total Current Liabilities ranged from a high of $804.4 million in FY2023 and a low of $305.4 million during FY2021.
  • Its 3-year average for Total Current Liabilities is $628.6 million, with a median of $738.1 million in 2024.
  • Per our database at Business Quant, UNITED THERAPEUTICS's Total Current Liabilities crashed by 30.17% in 2020 and then spiked by 134.38% in 2023.
  • UNITED THERAPEUTICS's Total Current Liabilities (Yearly) stood at $323.3 million in 2020, then fell by 5.54% to $305.4 million in 2021, then grew by 12.38% to $343.2 million in 2022, then soared by 134.38% to $804.4 million in 2023, then declined by 8.24% to $738.1 million in 2024.